Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by BioRestorative Therapies, Inc. (BRTX) on September 18, 2025. The company is incorporated in Nevada and trades on the NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders approved several key matters at the Annual Meeting:
- Director Elections: Class II directors Francisco Silva and David Rosa were elected. Silva received 1,591,913 votes for, while Rosa received 1,473,937 votes for. Significant broker non-votes (3,328,582) were recorded for both.
- Stock Incentive Plan Amendment: Stockholders approved increasing the authorized shares under the 2021 Stock Incentive Plan from 6,850,000 to 9,850,000. The vote was 1,340,653 for, 289,308 against, and 35,951 abstentions.
- Auditor Ratification: CBIZ CPAs P.C. was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 4,718,630 votes for and 271,000 against.
- Executive Compensation: The advisory vote on executive compensation passed with 1,539,396 votes for and 106,661 against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Investor Verification Checklist
- Verify the impact of the 3,000,000 share increase in the Stock Incentive Plan on potential future dilution.
- Review the proxy statement for details on the specific compensation packages approved in the advisory vote.
- Confirm the tenure and background of the newly elected Class II directors, Francisco Silva and David Rosa.
- Check subsequent filings for the company's financial performance for the fiscal year ending December 31, 2025, as no financial data was included in this 8-K.